Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Low-dose semaglutide spurs MASLD regression in people with HIV
Treatment with low-dose semaglutide helps reduce the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with HIV, according to data from the single-arm phase IIb ACTG A5371 trial.
Low-dose semaglutide spurs MASLD regression in people with HIV
21 Mar 2024Stopping TDF prophylaxis immediately postpartum feasible in highly viraemic CHB mothers
In highly viraemic pregnant women with chronic hepatitis B (CHB), stopping peripartum prophylaxis (PP) with tenofovir disoproxil fumarate (TDF) immediately after delivery does not increase the risk of relapse or retreatment vs TDF cessation at ≥4 weeks postpartum. Early withdrawal of PP-TDF, combined with standard neonatal immunization schemes, is 100 percent effective in preventing mother-to-child transmission (MTCT).
Stopping TDF prophylaxis immediately postpartum feasible in highly viraemic CHB mothers
19 Mar 2024Broaden screening in patients with TB or HBV, says study
Patients with hepatitis B virus (HBV) infection are at heightened risk of latent tuberculosis (TB), while those with latent TB are also at increased risk of HBV infection, reveals a study. Notably, the risk of co-infection is highest among Asians and those born in high-incidence countries.
Broaden screening in patients with TB or HBV, says study
17 Mar 2024Asian-adapted Mediterranean diet works well against fatty liver
In the TANGO* trial, a Mediterranean-like, culturally contextualized Asian diet rich in fibre and unsaturated fatty acids, induced multiple health benefits in Chinese women with nonalcoholic fatty liver disease (NAFLD), including weight loss.
Asian-adapted Mediterranean diet works well against fatty liver
15 Mar 2024Should experts rename ‘fatty liver disease’ to reduce stigma?
Individuals with nonalcoholic fatty liver disease (NAFLD) may face stigma from the disease or comorbidities, but the perceptions of shame differ across patients, healthcare providers, geographic locations, and subspecialties, reveals a study.
Should experts rename ‘fatty liver disease’ to reduce stigma?
11 Mar 2024Which factors predict mortality in advanced HCC?
A study has found the high bilirubin, pretreatment hypoalbuminemia, and biochemical tests indicative of hepatic or renal dysfunctions are independently associated with short-term mortality in patients with advanced hepatocellular cancer (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev).